Adrenal myelolipomas [0.03%]
肾上腺髓脂瘤
Jan Calissendorff,Carl Christofer Juhlin,Anders Sundin et al.
Jan Calissendorff et al.
Adrenal myelolipomas are benign, lipomatous tumours with elements of myeloid cells, most of which present as adrenal incidentalomas and comprise 3·3-6·5% of all adrenal masses. Adrenal myelolipomas are usually unilateral (in 95% of cases)...
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs [0.03%]
GLP-1受体激动剂：从降糖药到心血管药物
Darren K McGuire,Neha J Pagidipati
Darren K McGuire
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials [0.03%]
胰高糖素样肽1受体激动剂在2型糖尿病患者中的心血管、死亡和肾脏结局：随机试验的系统评价和meta分析
Naveed Sattar,Matthew M Y Lee,Søren L Kristensen et al.
Naveed Sattar et al.
Background: GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-base...
Clifford J Bailey
Clifford J Bailey
Paolo Quitadamo,Flora Caruso,Cristina Bucci et al.
Paolo Quitadamo et al.
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Ray Cavanaugh
Ray Cavanaugh
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial [0.03%]
利拉鲁肽对心血管高危超重和肥胖成人内脏脂肪和异位脂肪的影响：随机双盲安慰剂对照试验
Ian J Neeland,Steven P Marso,Colby R Ayers et al.
Ian J Neeland et al.
Background: Visceral and ectopic fat are key drivers of adverse cardiometabolic outcomes in obesity. We aimed to evaluate the effects of injectable liraglutide 3·0 mg daily on body fat distribution in adults with overwei...
Kishore M Gadde,Steven B Heymsfield
Kishore M Gadde